US FDA approves expanded use of Amgen's rare disease drug-March 2024-www.financetom.com

US FDA approves expanded use of Amgen's rare disease drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves expanded use of Amgen's rare disease drug

Apr 3, 2025 12:13 PM

April 3 (Reuters) - The U.S. Food and Drug

Administration has approved the expanded use of Amgen's ( AMGN )

drug, Uplizna, to help reduce the risk of flares in patients

with a rare immune system-related condition, the regulator said

on Thursday.

Previous page： Novo Nordisk's Once-Weekly Diabetes Drug Receives FDA Approval Next page： Novartis to Acquire Excellergy For Up to $2 Billion

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Novo Nordisk's Once-Weekly Diabetes Drug Receives FDA Approval

Mar 27, 2026

03:27 AM EDT, 03/27/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said late Thursday the US Food and Drug Administration has approved its experimental drug, Awiqli, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. The company said the drug is the first once-weekly basal insulin option, offering an alternative to...

Novartis to Acquire Excellergy For Up to $2 Billion

Mar 27, 2026

03:34 AM EDT, 03/27/2026 (MT Newswires) -- Novartis AG ( NVS ) said Friday it agreed to buy private biotechnology firm Excellergy for as much as $2 billion in initial and milestone payments. The proposed transaction includes an experimental early-stage IgE medication called Exl-111 designed to treat various allergic conditions, the company said. The clinical therapy targets a specific biological...

Bristow Group Insider Sold Shares Worth $1,347,049, According to a Recent SEC Filing

Mar 27, 2026

04:15 AM EDT, 03/27/2026 (MT Newswires) -- Christopher Scott Bradshaw, Director, President and Chief Executive Officer, on March 24, 2026, sold 29,625 shares in Bristow Group ( VTOL ) for $1,347,049. Following the Form 4 filing with the SEC, Bradshaw has control over a total of 302,938 common shares of the company, with 302,938 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1525221/000152522126000057/xslF345X05/form4.xml...

FOCUS-India's luxury promise hits a wall: not enough malls to shop in

Mar 27, 2026

* India is getting wealthier, but high-end retail space is scarce * Luxury brands have a tiny presence in India compared to China * New mall projects are coming, but relief is still years away * Franchises with local retailers provide faster access By Dhwani Pandya and Helen Reid MUMBAI/PARIS, March 27 (Reuters) - In India's rapidly growing economy, millions...